-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
International pharmaceutical giants such as AstraZeneca have developed new crown vaccines that have attracted attention
Mopivir is an oral antiviral drug
Mopivir is an oral antiviral drugMolnupiravir, before today, has always had this English name, here we can transliterate it as: "Mopivir", which is more convenient for everyone to understand
Figure 1 Molecular formula of Molnupiravir
Mopeville can reduce the death rate of the new crown
Mopeville can reduce the death rate of the new crownMopivir was originally designed as a flu drug, and even used clinically as a flu drug
Moupivir's oral dosage regimen
Moupivir's oral dosage regimenIn current clinical trials, the dosage regimen of Mupivir is: 400 mg twice a day, without hospitalization, directly applied to outpatients
Advantages of using oral drugs to treat the new crown
Advantages of using oral drugs to treat the new crownGenerally speaking, most acute viral infections are self-limiting diseases and do not require treatment.
Nevertheless, there is still a class of small molecule antiviral drugs that have achieved decisive efficacy in acute infections
summary
summaryIn short, Mupivir is a new type of potent ribonucleoside analog, which can inhibit the replication of a variety of RNA viruses including SARS-CoV-2
